Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2008-01-08
2008-01-08
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
C514S822000
Reexamination Certificate
active
07316911
ABSTRACT:
A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of α2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
REFERENCES:
patent: 4083961 (1978-04-01), Dussourdd'Hinterland et al.
patent: 4447236 (1984-05-01), Quinn
patent: 4610879 (1986-09-01), Markland et al.
patent: 4692139 (1987-09-01), Stiles
patent: 4755167 (1988-07-01), Thistle et al.
patent: 4812405 (1989-03-01), Lair et al.
patent: 4818700 (1989-04-01), Cregg et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4855231 (1989-08-01), Stroman et al.
patent: 4885242 (1989-12-01), Cregg
patent: 5167628 (1992-12-01), Boyles
patent: 5222941 (1993-06-01), Don Michael
patent: 5250034 (1993-10-01), Appling et al.
patent: 5370653 (1994-12-01), Cragg
patent: 5380273 (1995-01-01), Dubrul et al.
patent: 5498236 (1996-03-01), Dubrul et al.
patent: 5626564 (1997-05-01), Zhan et al.
patent: 5709676 (1998-01-01), Alt
patent: 5830468 (1998-11-01), Bini
patent: 5865176 (1999-02-01), Yock
patent: 5922322 (1999-07-01), Bini
patent: 5951981 (1999-09-01), Markland, Jr. et al.
patent: 6020181 (2000-02-01), Bini
patent: 6107280 (2000-08-01), White et al.
patent: 6261820 (2001-07-01), Boone et al.
patent: 6455269 (2002-09-01), Toombs
patent: 6759431 (2004-07-01), Hunter et al.
patent: 7033776 (2006-04-01), Toombs
patent: 7195903 (2007-03-01), Boone et al.
patent: 2002/0081685 (2002-06-01), Fox et al.
patent: 2005/0085769 (2005-04-01), MacMahon et al.
patent: 2006/0153896 (2006-07-01), Chu et al.
patent: 0 323 722 (1989-07-01), None
patent: 0 438 200 (1991-07-01), None
patent: 0 624 642 (1994-11-01), None
patent: 0 689 843 (1996-01-01), None
patent: WO 90/07352 (1990-07-01), None
patent: WO 96/36227 (1996-11-01), None
patent: WO 96/24917 (1998-06-01), None
patent: WO 98/46771 (1998-10-01), None
patent: WO 01/24817 (2001-04-01), None
patent: WO 01/25445 (2001-04-01), None
patent: WO 02/12283 (2002-02-01), None
[No authors listed],Annals of Surgery, 220(3):251-266 (1994).
Ahmed et al.,Haemostasis, 20:147-154 (1990).
Ahmed, N.K. “Biological and Thrombolytic Properties of Fibrolase,”Haemostasis, 20:334-340 (1990).
Barrett, A.J. (ed.),Methods in Enzymology, Academic Press, Inc., Philadelphia, PA, pp. 737-754 (1981).
Guan et al.,Archives of Biochemistry and Biophysics, 289(2):197-207 (1991).
Jackson and Clagett,Chest, 114:666S-682S (1998).
Kandarpa et al., “Forceful Pulsatile Local Infusion of Enzyme Accelerates Thrombolysis: In Vivo Evaluation of a New Delivery System,”Radiology, 168:739-744 (1981).
Manning,Toxicon, 33(9):1189-1200 (1995).
Markland et al., “Thrombolytic Effects of Recombinant Fibrolase or APSAC in a Canine Model of Carotid Artery Thrombosis,”Circulation, 90(5):2448-2456 (1994).
Ouriel et al.,Journal of Vascular Surgery, 19:1021-1030 (1994).
Ouriel et al.,New England Journal of Medicine, 338:1105-1111 (1998).
Pretzer et al.,Pharmaceutical Research, 8(9):1103-1112 (1991).
Pretzer et al.,Pharmaceutical Research, 9(7):870-877 (1992).
Randolph et al.,Protein Science, Cambridge University Press, pp. 590-600 (1992).
Retzios et al.,Thrombosis Research, 74(4):355-367 (1994).
International Search Report dated Oct. 21, 2003.
Loayza et al., “Resolution of isoforms of natural and recombinant fibrolase, the fibrinolytic enzyme from Agkistrodon contortrix contortix snake venom, and comparison of their EDTA sensitivities,”Journal of Chromatography B 662:227-243 (1994).
Rholam et al., “Role of amino acid sequences flanking dibasic cleavage sites in precursor proteolytic processing—The importance of the first residue C-terminal of the cleavage site,”European Journal of Biochemistry 227:707-714 (1995).
Sreekrishna et al., “Strategies for optimal sysnthesis and secretion of heterologous proteins in the methylotrophic yeastPichis pastoris,” Gene 190:55-62 (1997).
Potempa et al., “Stabilization vs. degradation ofStaphylococcus aureusmetalloproteinase,”Biochimica et Biophysica Acia, 993:301-304 (1989).
Williams et al., “The lyophilization of pharmaceuticals: a literature review,”J. Parenter Sci Technol 38:48-59 (1984).
Chen, “Formulation Concerns of Protein Drugs,”Drug Development and Industrial Pharmacy, 18(11-12):1311-1354 (1992).
Carpenter et al., “Interactions of Stabilizing Additives with Proteins During Freeze-Thawing and Freeze-Drying,”Developments in Biological Standardization 74:225-239 (1991).
Markland et al., “Resolution of Isoforms of Natural and Recombinant Fibrinolytic Snake Venom Enzyme Using High Performance Capillary Electrophoresis,”Journal of Liquid Chromatography 16(1-10): 2189-2201 (1993).
Selistre de Araujo et al., “Molecular Cloming and Sequence Analysis of CDNAS for Metalloproteinases from Broad-Banded Copperhead Agkistrodon Contortrix Laticinctus”, Archives of Biochemistry and Biophysics 320(1):141-148 (1995).
Anai et al., “Inhibition of a Snake Venom Hemorrhagic Metalloproteinase by Human and Rat Alpha-Macroglobulins,” Toxicon: Official Journal of the International Society on Toxinology , 36(8):1127-1139 (1998).
Bode et al., Astacins, Serralysins, Snake Venom and Matrix Metalloproteinases Exhibit Identical Zinc-Binding Environments (Hexxhxxgxxh and Met-Turn) and Topologies and Should be Grouped Into a Common Family, The ‘Metzincins’, FEBS Lett., 331(1-2):134-140 (1993).
Stocker et al., “The Metzincins-Topological and Sequential Relations Between the Astacins, Adamalysins, Serralysins, and Matrixins (Collagenases Define a Superfamily of Zinc-Peptidases,” Protein Sci., 4(5):823-840 (1995).
Verstraete et al., “Thrombolytic Agents in Development,” Drugs, 50(1):29-42 (1995).
Toombs, et al., “Rapid Thrombolysis and Reduced Hemorrhagic Complications with Fibrolase and a Novel Acting Thrombolytic (NAT): Comparison to Plasminogen Activators in Piglets and Rats,”Blood 96(11):56A-57A (2000).
Toombs, “Alfimeprase: Pharmacology of a Novel Fibrinolytic Metalloproteinase for Thrombolysis,”Haemostasis 31(3-6):141-147 (2001).
Amgen Inc.
Gitomer Ralph
Robins & Pasternak LLP
LandOfFree
Method for treatment of indwelling catheter occlusion using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of indwelling catheter occlusion using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of indwelling catheter occlusion using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2764511